Translational Medicine Research Collaboration

Osama Albarbarawi, PhD

1. Capitán-Vallvey, L., Al-Barbarawi, O., Fernández-Ramos, M.D., & Avidad, R., Use of optically transparent membranes for preconcentration and direct phosphorimetric determination of pharmaceutical flumequine. Journal of Analytical Chemistry 60 (11), 1009–1013 (2005).

2. Capitán-Vallvey, L.F., M.A. Al-Barbarawi, O., Fernández-Ramos, M., & Avidad, R., Membrane preconcentration of nalidixic and piromidic acids and simultaneous determination using a synchronous solid-phase phosphorescence approach. 37 (13), 2669-2683L (2004).

3. Capitán-Vallvey, L.F., Determination of oxolinic acid in cow´s milk and human urine by means of a single-use phosphorimetric sensor. Talanta 60, 247-255 (2003).

4. Capitan-Vallvey, L.F., al-Barbarawi, O.M., Fernandez-Ramos, M.D., Avidad, R., & Ramirez Gonzalez, V., Single-use phosphorimetric sensor for the determination of nalidixic acid in human urine and milk. The Analyst 125 (11), 2000-2005 (2000).

Lindyanne Alexander, MSc

1. Sharp, L. et al., Reasons for participation and non-participation in a randomized controlled trial: postal questionnaire surveys of women eligible for TOMBOLA (Trial Of Management of Borderline and Other Low-Grade Abnormal smears). Clinical trials (London, England) 3 (5), 431-442 (2006).

2. Cotton, S.C. et al., Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design. Contemporary clinical trials 27 (5), 449-471 (2006).

Abdel Atrith, PhD

1. Izquierdo, L., Atrih, A., Rodrigues, J.A., Jones, D.C., & Ferguson, M.A., Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase has unusual substrate specificity and protects the parasite from stress. Eukaryotic cell 8 (2), 230-240 (2009).

2. Skidmore, M., Atrih, A., Yates, E., & Turnbull, J.E., Labelling heparan sulphate saccharides with chromophore, fluorescence and mass tags for HPLC and MS separations. Methods in molecular biology (Clifton, N.J 534, 157-169 (2009).

3. Bates, S. et al., Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. The Journal of biological chemistry 281 (1), 90-98 (2006).

4. Atrih, A., Richardson, J.M., Prescott, A.R., & Ferguson, M.A., Trypanosoma brucei glycoproteins contain novel giant poly-N-acetyllactosamine carbohydrate chains. The Journal of biological chemistry 280 (2), 865-871 (2005).

Alun Barton

1. McLoone, P., Simics, E., Barton, A., Norval, M., & Gibbs, N.K., An action spectrum for the production of cis-urocanic acid in human skin in vivo. The Journal of investigative dermatology 124 (5), 1071-1074 (2005).

2. Jones, C.D., Barton, A.K., Crosby, J., Norval, M., & Gibbs, N.K., Investigating the red shift between in vitro and in vivo urocanic acid photoisomerization action spectra. Photochemistry and photobiology 63 (3), 302-305 (1996).

Mark Beggs, PhD MA (oxons)

1. Beggs, M., Getting Automation to Deliver. Amercian Drug Discovery 3 (5), 34-37 (2008).

2. Beggs, M., V.L, E., & J.R, A., High Throughput Screening (Review) in Industrialisation of Drug Discovery. (Marcel Dekker Inc., New York, 2008).

3. Wollerton, M.C., R, W., J.A, B., I.R, H., & M, B., Automation and optimization of protein expression and purification on a novel robotic platform. Journal for the Association of Laboratory Automation 11 (5), 291-303 (2006).

4. Peakman, T., Franks, S., White, C., & Beggs, M., Harnessing the power of Discovery in large pharmaceutical organisations. Closing the productivity gap. Drug Discovery Today 8 (5), 203-211 (2003).

5. Beggs, M., Outsourcing Discovery: A route to increasing productivity. American Laboratory 32 (14), 32-36 (2000).

6. Beggs, M., A route to increasing productivity. American Laboratory 32 (14), 32-36 (2000).

7. Beggs, M. & J.S, M., Flexible Use of People and Machines (Review) in High Throughput Screening. The Discovery of Bioactive Substances eds Devlin J., Marcel Dekker Inc., New York, 471-481 (1997).

8. Beggs, M., Use of a Two Armed Robot for High Throughput Screening Journal of Biomolecular Screening 2, 71-78 (1997).

9. Beggs, M. et al., Interleukin-1 beta inhibits glucokinase activity in clonal HIT-T15 beta-cells. FEBS Lett 267 (2), 217-220 (1990).

10. Beggs, M., Shaw, J.M., & Randle, P.J., Longer-term regulation of branched-chain-2-oxoacid dehydrogenase complex studied in rat hepatocytes in culture. The Biochemical journal 257 (1), 271-275 (1989).

11. Espinal, J., Beggs, M., & P.J, R., Assay of Branched Chain a-Keto Acid Dehydrogenase Kinase in Mitochondrial Extracts and Purified Branched Chain ?-Keto Acid Dehydrogenase Complexes Methods in Enzymology 166, 166-175 (1988).

Jeff Brady, PhD

1. Burch, L.R., et al., A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children. The Journal of clinical endocrinology and metabolism 94 (7), 2587-2593 (2009).

2. Brady, J., Wilson, L., McGregor, L., Valente, E., & Orning, L., Active B12: a rapid, automated assay for holotranscobalamin on the Abbott AxSYM analyzer. Clinical chemistry 54 (3), 567-573 (2008).

3. Orning, L. et al., Characterization of a monoclonal antibody with specificity for holo-transcobalamin. Nutrition & metabolism 3, 3 (2006).

4. Brady, J.D. & Robins, S.P., Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. The Journal of biological chemistry 276 (22), 18812-18818 (2001).

Catharine Goddard, PhD

1. Burch, L.R, et al., A single nucleotide polymorphism on exon-4 of the gene encoding PPAR{delta} is associated with reduced height in adults and children. J Clin Endocrinol Metab. jc.2009-0392 (2009)
2. Feuerstein, G., Wan, HI, Walsh, F, Goddard, C, Parsons, S, Coughlin, CM, Rutkowski, L, Alesci, S, Lee, JH, Koening, W, Smith, M, Surrogate diseases’ pave the way for successful proof-of-concept studies towards investment decisions in large morbidity and mortality outcome studies in major diseases. American Drug Discovery Translational Medicine perspectives in Drug Discovery and Development –PartIV 3, 26-32 (2008).

3. Goddard, C.A. et al., Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts. Acta physiologica (Oxford, England) 194 (2), 123-140 (2008).

4. Gordon, A.R. et al., Splenomegaly and modified erythropoiesis in KLF13-/- mice. The Journal of biological chemistry 283 (18), 11897-11904 (2008).

5. Sabir, I.N. et al., Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome. Pflugers Arch 455 (4), 637-651 (2008)

6. Stokoe, K.S. et al., Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. The Journal of physiology 578 (Pt 1), 69-84 (2007).

7. Lei, M. et al., Sinus node dysfunction following targeted disruption of the murine cardiac sodium channel gene Scn5a. The Journal of physiology 567 (Pt 2), 387-400 (2005).

8. Jones, G.L. et al., A functional analysis of mouse models of cardiac disease through metabolic profiling. The Journal of biological chemistry 280 (9), 7530-7539 (2005).

9. Goddard, C.A., Evans, M.J., & Colledge, W.H., Genistein activates CFTR-mediated Cl(-) secretion in the murine trachea and colon. Am J Physiol Cell Physiol 279 (2), C383-392 (2000).

10. Scott, E.S., Goddard, C.A., Wiseman, J.W., Evans, M.J., & Colledge, W.H., A murine tracheal culture system to investigate parameters affecting gene therapy for cystic fibrosis. Gene Ther 7 (7), 612-618 (2000).
    

11. Goddard, C.A. et al., A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. Gene Ther 4 (11), 1231-1236 (1997).

Garry Honey, PhD

1. Chan, K.W. et al., Identifying Common and Distinct Psychopathological Profiles of Pharmacological Models of Schizophrenia
   

2. Honey, G.D. et al., Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. J Neurosci 28 (25), 6295-6303 (2008).

3. Murray, G.K. et al., Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Molecular psychiatry 13 (3), 239, 267-276 (2008).

4. Corlett, P.R. et al., Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 130 (Pt 9), 2387-2400 (2007).

5. Corlett, P.R., Honey, G.D., & Fletcher, P.C., From prediction error to psychosis: ketamine as a pharmacological model of delusions. Journal of psychopharmacology (Oxford, England) 21 (3), 238-252 (2007).

6. Absalom, A.R. et al., Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. British journal of anaesthesia 98 (5), 615-623 (2007).

7. Matthews, P.M., Honey, G.D., & Bullmore, E.T., Applications of fMRI in translational medicine and clinical practice. Nature reviews 7 (9), 732-744 (2006).

8. Corlett, P.R. et al., Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Archives of general psychiatry 63 (6), 611-621 (2006).

9. Pomarol-Clotet, E. et al., The Effects of Ketamine on Normal Subjects – a Phenomenological Study. British Journal of Psychiatry. 189, 173-179 (2006).

10. Fu, C.H. et al., Modulation of effective connectivity by cognitive demand in phonological verbal fluency. NeuroImage 30 (1), 266-271 (2006).

11. Fletcher, P.C. & Honey, G.D., Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends in cognitive sciences 10 (4), 167-174 (2006).
12. Trends in Cognitive Sciences. 2206;10(4):167-74
13. Honey, G.D. & Fletcher, P.C., Investigating principles of human brain function underlying working memory: what insights from schizophrenia? Neuroscience 139 (1), 59-71 (2006).

14. Honey, G.D. et al., The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology 31 (2), 413-423 (2006).

15. Honey, G.D. et al., Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function. Brain 128 (Pt 11), 2597-2611 (2005).

16. Muller, U. et al., Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology 180 (4), 624-633 (2005).

17. Honey, G.D. et al., Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15 (6), 749-759 (2005).

18. Honey, G. et al., Sub-psychotic doses of ketamine disrupt memory encoding processes facilitating subsequent recollection. Psychopharmacology. 28 (11), 2037-2044 (2005).

19. Corlett, P.R. et al., Prediction error during retrospective revaluation of causal associations in humans: fMRI evidence in favor of an associative model of learning. Neuron 44 (5), 877-888 (2004).

20. Honey, G. & Bullmore, E., Human pharmacological MRI. Trends in pharmacological sciences 25 (7), 366-374 (2004).

21. Honey, R.A. et al., Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology 29 (6), 1203-1214 (2004).

22. Honey, G. et al., Dopaminergic modulation of nigrostriatal functional and effective connectivity in a paired associate learning task. Brain (126) (2003).

23. Honey, G.D. et al., The functional neuroanatomy of schizophrenic subsyndromes. Psychological medicine 33 (6), 1007-1018 (2003).

24. Bullmore, E. et al., Practice and difficulty evoke anatomically and pharmacologically dissociable brain activation dynamics. Cereb Cortex 13 (2), 144-154 (2003).

25. Honey, R.A. et al., Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 28 (11), 2037-2044 (2003).

26. Honey, G., PC, F., & ET., B., Psychopathology and Neuroimaging. Journal of Neurology, Neurosurgery & Psychiatry. 72 (4), 432-439 (2002).

27. Honey, G.D., Bullmore, E.T., & Sharma, T., De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophrenia research 53 (1-2), 45-56 (2002).

28. Honey, G.D. et al., Effects of verbal working memory load on corticocortical connectivity modeled by path analysis of functional magnetic resonance imaging data. NeuroImage 17 (2), 573-582 (2002).

29. Honey, G. & ET, B., Functional Neuroimaging and Schizophrenia. Psychiatry 1 (1), 26-29 (2002).

30. Kumari, V. et al., Neural correlates of procedural learning. Schizophrenia research 57 (1), 97-107 (2002).

31. Welchew, D.E., Honey, G.D., Sharma, T., Robbins, T.W., & Bullmore, E.T., Multidimensional scaling of integrated neurocognitive function and schizophrenia as a disconnexion disorder. NeuroImage 17 (3), 1227-1239 (2002).

32. Honey, G.D., Bullmore, E.T., & Sharma, T., Prolonged reaction time to a verbal working memory task predicts increased power of posterior parietal cortical activation. NeuroImage 12 (5), 495-503 (2000).

33. Bullmore, E. et al., How good is good enough in path analysis of fMRI data? NeuroImage 11 (4), 289-301 (2000).

34. Longworth, C., Honey GD, Sharma T, The emerging role of functional magnetic resonance imaging in neuropsychiatry. British Medical Journal (1999).

35. Honey, G.D. et al., Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 96 (23), 13432-13437 (1999).

BOOK CHAPTERS

1. Honey, D.G., Psychopharmacological Modelling of Psychiatric Illness. In Handbook of Neuropsychology of Mental Illness. Cambridge University Press: Cambridge(2009).

2. Wood, N., Allen, C., Pantelis (eds). Cambridge University Press: Cambridge.

3. Honey, G. & ET, B., Functional MRI and Pharmacology: What Role in Clinical Practice? In Clinical Applications of Functional Brain MRI. Oxford University Press: New York (S. Rombouts, P Scheltens, F. Barkhof (eds) (2007).

4. Honey, G., McGuire PK, Bullmore ET, Functional magnetic resonance imaging (fMRI) in schizophrenia. In: Schizophrenia: From Neuroimaging to Neuroscience. Oxford University Press: New York S. Lawrie, E. Johnstone, D. Weinberger (eds). (2004).

5. Honey, G.D. Functional neuroimaging in schizophrenia: confounds and controversies. Doctoral Thesis. Institute of Psychiatry, University of London (2001).

Jeffrey Huang, PhD

1. Lan, M.J. et al., Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Molecular psychiatry 14 (3), 269-279 (2009).

2. Craddock, R.T., Huang, T.-J., E, J., N, H., & S, B., Differential Expression of Alpha-Defensins in T Cells from Patients with Schizophrenia. Mol. Cell. Proteomics Jul;7 (7), 1204-1213 (2008).

3. Huang, T.-J. et al., Metabolic and proteomic profile of cerebral spinal fluid from patients with prodromal psychosis. PLoS ONE, 2(1):e756 (2008).

4. Huang, J.T. et al., Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Molecular psychiatry 13 (12), 1118-1128 (2008).

5. Huang, J.T. et al., Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS medicine 3 (11), e428 (2006).

6. Holmes, E. et al., Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS medicine 3 (8), e327 (2006).

Stephen McGuinness

1. Kean, D.E. et al., Differential polarization of immune responses by plant 2S seed albumins, Ber e 1, and SFA8. J Immunol 177 (3), 1561-1566 (2006).

2. Goodridge, H.S. et al., Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite immunology 29 (3), 127-137 (2007).

3. Harnett, M.M. et al., The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis. Annals of the rheumatic diseases 67 (4), 518-523 (2008).

Gino Miele, PhD

1. Miele, G. et al., Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS ONE 3 (12), e3870 (2008).

2. Appleford, N. E., et al., alpha-Hemoglobin stabilizing protein is not a suitable marker for a screening test for variant Creutzfeldt-Jakob disease. Transfusion 48 (8), 1616-26 (2008).

3. Kranich, J. et al., Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. The Journal of experimental medicine 205 (6), 1293-1302 (2008).
   

4. Kennedy, L. et al., Hematopoietic Lineage Transcriptome Stability and Representation in PAXgene Collected Peripheral Blood Utilising SPIA Single-Stranded cDNA Probes for Microarray. Biomarker insights 3, 403-417 (2008).

5. Julius, C. et al., Transcriptional stability of cultured cells upon prion infection. J Mol Biol 375 (5), 1222-1233 (2008).

6. Seeger, H. et al., Coincident scrapie infection and nephritis lead to urinary prion excretion. Science (New York, N.Y 310 (5746), 324-326 (2005).

7. Huber, C. et al., Lymphotoxin-beta receptor-dependent genes in lymph node and follicular dendritic cell transcriptomes. J Immunol 174 (9), 5526-5536 (2005).

8. Polymenidou, M. et al., Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proceedings of the National Academy of Sciences of the United States of America 101 Suppl 2, 14670-14676 (2004).

9. Aguzzi, A., Heikenwalder, M., & Miele, G., Progress and problems in the biology, diagnostics, and therapeutics of prion diseases. The Journal of clinical investigation 114 (2), 153-160 (2004).

10. Genoud, N. et al., Disruption of Doppel prevents neurodegeneration in mice with extensive Prnp deletions. Proceedings of the National Academy of Sciences of the United States of America 101 (12), 4198-4203 (2004).

11. Miele, G., Manson, J., & Clinton, M., A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nature medicine 7 (3), 361-364 (2001).

12. Miele, G., MacRae, L., McBride, D., Manson, J., & Clinton, M., Elimination of false positives generated through PCR re-amplification of differential display cDNA. BioTechniques 25 (1), 138-144 (1998).

13. Miele, G. & Lever, A.M., Expression of mutant and wild-type gag proteins for gene therapy in HIV-1 infection. Gene Ther 3 (4), 357-361 (1996).

14. Miele, G., Mouland, A., Harrison, G.P., Cohen, E., & Lever, A.M., The human immunodeficiency virus type 1 5' packaging signal structure affects translation but does not function as an internal ribosome entry site structure. J Virol 70 (2), 944-951 (1996).

Steve Moore, PhD, M I Biol

1. Holbrook, J.D. et al., Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 108 (2), 384-396 (2009).
   

2. Weil, A., Moore, S.E., Waite, N.J., Randall, A., & Gunthorpe, M.J., Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8. Molecular pharmacology 68 (2), 518-527 (2005).
   

3. Neylon, C.B. et al., Intermediate-conductance calcium-activated potassium channels in enteric neurones of the mouse: pharmacological, molecular and immunochemical evidence for their role in mediating the slow afterhyperpolarization. J Neurochem 90 (6), 1414-1422 (2004).
   

4. Osborne, S.L., Corcoran, S.L., Prinjha, R.K., & Moore, S.E., Nogo A expression in the adult enteric nervous system. Neurogastroenterol Motil 16 (4), 465-474 (2004).

5. Skaper, S.D., Moore, S.E., & Walsh, F.S., Cell signalling cascades regulating neuronal growth-promoting and inhibitory cues. Progress in neurobiology 65 (6), 593-608 (2001).

6. Vinson, M. et al., Myelin-associated glycoprotein interacts with ganglioside GT1b. A mechanism for neurite outgrowth inhibition. The Journal of biological chemistry 276 (23), 20280-20285 (2001).

7. Giger, J. et al., Neuropilin-2 is required in vivo for development of multiple axonal projections within the CNS and PNS. Neuron Vol 25 (1), 29-41 (2000).

8. Prinjha, R., Cloning and functional expression of Nogo, a potent neurite outgrowth inhibitory factor. Nature 403, 383-384 (2000).

Grant Sellar, DPhil

1. Fleming, J.S., McQuillan, H.J., Millier, M.J., & Sellar, G.C., Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract. Reproduction (Cambridge, England) 137 (4), 721-726 (2009).

2. Sellar, G., Alvarez, J.D., Loganzo, F., Abbas, R., Immermann, F., Karnoub, M., Feuerstein, G.Z., Burczynski, M.E., and Coughlin, C.M., The opportunity posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics. Biomarkers in Medicine, 2 (2), 147-153. (2008).

3. Tomlinson, V.A. et al., Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. British journal of cancer 96 (10), 1613-1620 (2007).

4. Ntougkos, E. et al., The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates. Clin Cancer Res 11 (16), 5764-5768 (2005).

5. Sellar, G.C. et al., Epigenetically Inactivated and Has Tumor-Suppressor Function in Epithelial Ovarian Cancer. Nat. Genet. 34: 337-343 (2003).

Fiona Wilson, PhD

1. Wilson, F.A. et al., Tissue methionine cycle activity and homocysteine metabolism in female rats: impact of dietary methionine and folate plus choline. American journal of physiology 296 (4), E702-713 (2009).
   

2. Wilson, F.A. et al., Fed levels of amino acids are required for the somatotropin-induced increase in muscle protein synthesis. American journal of physiology 295 (4), E876-883 (2008).

3. Wilson, F.A. et al., Stimulation of muscle protein synthesis by somatotropin in pigs is independent of the somatotropin-induced increase in circulating insulin. American journal of physiology 295 (1), E187-194 (2008).

Runxuan Zhang, PhD

1. Vandenbogaert, M. et al., Alignment of LC-MS images, with applications to biomarker discovery and protein identification. Proteomics 8 (4), 650-672. (2008).

2. Tafelmeyer, P. et al., Comprehensive proteome analysis of Mycobacterium ulcerans and quantitative comparison of mycolactone biosynthesis. Proteomics 8 (15), 3124-3138 (2008).

3. Zhang, R., Huang, G.B., Sundararajan, N., & Saratchandran, P., Multi-category classification using an Extreme Learning Machine for microarray gene expression cancer diagnosis. IEEE/ACM transactions on computational biology and bioinformatics / IEEE, ACM 4 (3), 485-495 (2007).

4. Zhang, R., Huangm, G., Sundararajan, N., & Saratchandran, P., Improved GAP-RBF Network for Classification Problems. Neurocomputing vol.70, 3011-3018 (2007).

5. Zhang, R. & Qiu, Z., Independent Component Analysis based Signal and Noise Separation for Evoked Potentials. Journal of Beijing Biomedical Engineering vol.22 (2), 85-88 (2003).

6. Ning Xie, R.Z., Tianshuang Qiu and Xuxiu Zhang, An Independent Component Analysis Based Signal Separation Method for Evoked Potentials. Journal of Dalian Railway Institute vol.23 (2), 62-65 (2002).